Enzalutamide: A Review of Its Use in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

@article{Keating2015EnzalutamideAR,
  title={Enzalutamide: A Review of Its Use in Chemotherapy-Na{\"i}ve Metastatic Castration-Resistant Prostate Cancer},
  author={Gillian M. Keating},
  journal={Drugs \& Aging},
  year={2015},
  volume={32},
  pages={243-249}
}
  • G. Keating
  • Published 25 February 2015
  • Medicine
  • Drugs & Aging
Enzalutamide (Xtandi®) is an androgen receptor inhibitor that blocks several steps in the androgen receptor signalling pathway. This article reviews the clinical efficacy and tolerability of oral enzalutamide in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC), as well as summarizing its pharmacological properties. In the randomized, double-blind, multinational PREVAIL trial, enzalutamide significantly improved both radiographic progression-free survival and… 

Enzalutamide: A Review in Castration-Resistant Prostate Cancer

TLDR
Ezalutamide is an emerging option for the treatment of men with nonmetastatic CRPC who are at high-risk for developing metastatic disease, and remains an important first-line option in chemotherapy-naive or -experienced patients with metastaticCRPC.

Androgen Receptor as a Potential Target for Treatment of Breast Cancer

  • Y. WuJ. Vadgama
  • Biology, Medicine
    International journal of cancer research and molecular mechanisms
  • 2017
TLDR
The role of AR in different subtypes of breast cancers is reviewed and its mechanisms are elucidated to better understand its mechanisms.

Quantitative Study of Impurities in Enzalutamide and Identification, Isolation, Characterization of Its Four Degradation Products Using HPLC, Semi-preparative LC, LC/ESI–MS and NMR Analyses

Enzalutamide was recently approved for the treatment of castration-resistant prostate cancer. In this study, the related substances in enzalutamide bulk substance were analyzed qualitatively and

Crystal Forms of Enzalutamide and a Crystal Engineering Route to Drug Purification

The crystal forms of the active pharmaceutical ingredient enzalutamide, a drug used for the treatment of metastatic prostate cancer, have been investigated by X-ray, thermogravimetric analysis, and

References

SHOWING 1-10 OF 48 REFERENCES

Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer

TLDR
In a randomized, double-blind, placebo-controlled, multinational, phase III trial in patients with mCRPC progressing after docetaxel therapy, enzalutamide significantly prolonged overall survival, delayed prostate specific antigen progression and prolonged radiographic progression-free survival and time to the first skeletal event.

Enzalutamide in metastatic prostate cancer before chemotherapy.

TLDR
Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer.

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all

TLDR
Although a large majority of patients responded favorably to enzalutamide in the prechemotherapy setting, a small but significant proportion of patients demonstrated no meaningful benefit to this agent, highlighting an important concept in the understanding of this disease: inherent and acquired resistance to AR-targeting therapies.

Increased survival with enzalutamide in prostate cancer after chemotherapy.

TLDR
Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy, and was shown with respect to all secondary end points.

767PRESPONSE RATES AND OUTCOMES WITH ENZALUTAMIDE FOR PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER AND VISCERAL DISEASE IN THE PREVAIL TRIAL.

  • C. HiganoJ. Alumkal T. Beer
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2014
TLDR
The results support androgen receptor signaling as an important target in prostate cancer with visceral metastases in men with chemotherapy-naive men with asymptomatic or mildly symptomatic mCRPC.

Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate

TLDR
Previous abiraterone therapy is associated with a less marked fall in PSA following enzalutamide therapy in post-chemotherapy mCRPC patients compared with reported results in randomized trials.

Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience.

TLDR
Primary outcomes were PSA response rate (confirmed decline ≥ 50%) and time to treatment failure (TTF, defined as the time from treatment initiation to treatment discontinuation for any reason, including disease progression, treatment toxicity, patient preference, or death.).

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

TLDR
Abiraterone and prednisolone have modest antitumour activities in patients with mCRPC pretreated with docetaxel and enzalutamide.